Expression And Gene Copy Number Analysis Of ERBB2 Oncogene In Prostate Cancer

Below is result for Expression And Gene Copy Number Analysis Of ERBB2 Oncogene In Prostate Cancer in PDF format. You can download or read online all document for free, but please respect copyrighted ebooks. This site does not host PDF files, all document are the property of their respective owners.

Novel Oncogene Induced Metastatic Prostate Cancer Cell Lines

Nov 30, 2012 expression and/or copy number in up to 30% of prostate tumors. Murine prostate tumors induced by prostate targeted c-Myc give rise to tumors with molecular features of human prostate cancer (8). c-Myc, which is overexpressed in human prostate cancer is sufficient to induce prostatic intraepithelial neoplasia (PIN) in transgenic mice (8).


SUPPLEMENT: network and Pathway analysis of Cancer susceptibility (B) CITATI oN: rouam et al. Identifying Driver Genes in Cancer by triangulating Gene expression, Gene Location, and survival Data

AD Award Number: W81XWH-12-1-0062 TITLE: Molecular

prostate cancer, the region encompassing NEK6 at chromosome 9q33.3 is present in a region of recurrent copy number gain (Taylor et al., 2010; Huang et al., 2012; Grasso et al., 2012) without a known validated prostate cancer oncogene, suggesting a possible role in prostate cancer pathogenesis. In addition to conferring

Laboratory Testing for Her2 Status in Breast Cancer

Tested by immunohistochemistry; immunoreactivity in 1% or more cancer cells is considered positive 1 Her2: Growth factor receptor Encoded by gene ERBB2, also known as Her2/neu, V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog, etc. Tested by immunohistochemistry and/or in situ hybridization 6 1

Table S5. Literature of association between non-cancer genes

prostate cancer : Understanding the lethal variant of prostate cancer: power of examining extremes neuroblastoma Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene : colorectal cancer Relationship of increased aurora kinase A gene copy number, prognosis and

Metastatic castration-resistant prostate cancer reveals

Mutational and copy number analyses from epithelial tumors have identified several activating tyrosine kinase mutations and amplifications, such as epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma and erythroblastic leukemia viral oncogene homolog 2 (ERBB2 or HER2/neu) gene amplification in breast cancer (1).

Research Paper Cytotoxicity of a Natural Anthraquinone (Aloin

In breast cancer several DNA aberrations have been recognized, including gene ampli-fication and loss of different chromosomal regions, which affect the sensitivity of tumors to chemotherapy. c-ErbB-2 oncogene, localized on chromosome 17q12-21, is the most frequently amplified oncogene in breast cancer.1 Initially detected as a transforming gene,

An integrative analysis reveals functional targets of GATA6

Worldwide, stomach cancer is the second leading cause of cancer death (10, 11). Somatic copy number amplifications (SCNAs) or mutations of ERBB2, EGFR, MET, and FGFR2 offer avenues for targeted therapy in few patients (12 14). Esophageal adenocarcinomas, which are closely related, frequently amplify GATA6 and GATA4 (7), TF gene loci that

Gene Expression Regulation Lesson 4 Dr. Daniela Barilà

All Cancers Excluding Non-Melanoma Skin Cancer (C00-97 Excl. C44) Average Number new Cases Per Year and Age-Specific Incidence Rates, UK, 2006-2008 Figure 11.7 The Biology of Cancer (© Garland Science 2007)

Gene Amplification as a Prognostic Factor in Primary Brain

erbB2 with breast cancer, and C-myc amplification in squamous cell carcinoma of the lung (8, 9). In the case of neuroblastoma, the higher the copy number of the N-myc gene, the worse the prognosis (10). For breast cancer, either amplification or in-creased expression of the protein product of C-erbB2 is associ-

An integrative analysis reveals functional targets of GATA6

cancer3 and AR in prostate cancer.4 As tumors may depend on amplified TF genes,2,3 they are potential targets for cancer therapy. However, TFs other than nuclear hormone receptors are notoriously difficult drug targets.5,6 Therefore, core downstream genes and pathways might suggest alternative targets that are more sensitive to small molecules.

CD74 NRG1 Fusions in Lung Adenocarcinoma - Cancer Discovery

receptor complexes. Accordingly, ERBB2 and ERBB3 expression was high in the index case, and expres-sion of phospho-ERBB3 was specifi cally found in tumors bearing the fusion ( P < 0.0001). Ectopic expression of CD74 NRG1 in lung cancer cell lines expressing ERBB2 and ERBB3 activated ERBB3

Clinical Appropriateness Guidelines Molecular Testing of

Molecular testing and gene expression profiling for occult neoplasms (cancers of unknown primary) is experimental, investigational and unproven. Prostate Cancer Prostate cancer early detection assays are medically necessary as outlined in the criteria put forth by NCCN ®

Aikaterini Emmanouilidi and Marco Falasca * ID

Oct 24, 2017 part of the pathway PDK1 is also implicated in cancer, in the majority of the cases though it is the overexpression that leads to pathologic conditions, rather than mutations. For instance, increase in gene copy number and protein overexpression have been reported in breast cancer and acute myeloid leukaemia, among other malignancies [23].

Amplification and Overexpression of ERBB2, uPA, TRPS1, EIF3S3

Visakorpi€ T€ (2002):€ € Expression€ and€ gene€ copy€ number€ analysis€ ofERBB2 oncogene€in€prostate€cancer.€Am€J€Pathol€160:339­345. II.€ Helenius€ MA,€ Savinainen€ KJ,€ Bova€ GS€ and€ Visakorpi€ T€ (2006):

ErbB2/Her-2RegulatestheExpressionofAkt2 inProstateCancerCells

naling pathway leading to Akt and NF-kappaB activation in prostate cancer cells. In this study, the regulation of Akt2 expression in LNCaP, DU145, and PC-3 prostate cancer cell lines was investigated.

Cyfip1 Is a Putative Invasion Suppressor in Epithelial Cancers

liver, 23 prostate, 21 melanoma, 17 CLL, and 13 AML. Cancer cell lines were from ATCC and included 34 breast, 29 colon, and 8 lung cancer cell lines. High-resolution genomic profiling of DNA copy number alterations was performed as previously described (Hicks et al., 2006).

Lung adenocarcinoma genomics

Gene expression and transcriptome cancer deaths in the U.S. each year Prostate Colon & rectum 2007: copy number analysis of 371 cases, discovered NKX2-1 and

Identification and validation of dysregulated - BMC Cancer

lence MAPK7 gene expression. Cell lines were trans-fected over a 4-day period and cell lysates were taken for Western blot analysis of MAPK7 protein expression (Fig. 3b). In the MAPK7 dysregulated cell lines KYSE30 and SNU449, MAPK7 protein expression was reduced by 90 and 70 % respectively, using three separate MAPK7 siRNA constructs.

Oncogenic EGFR Signaling Networks in Glioma

ErbB2 receptor abundance without changes in gene copy number are more likely to have a clinical outcome similar to that of patients who do not express ErbB2 compared to those with both ErbB2 recep-tor overexpression and gene amplification (26). This finding would suggest that there may be underlying biological and signaling

Driver Fusions and Their Implications in the Development and

We integrated gene expres-sion, copy number, and fusion annotations to systematically test for associations between gene expression and fusion status. For each fusion having an oncogene, kinase, or tumor sup-pressorgene(TSG)(TableS2),wedeterminedwhetherthatsam-ple was an expression outlier for that gene and subsequently


across multiple prostate cancer gene expression data sets. ETV1 and ERG expression (normalized expression units) are shown from all profiled samples in two-large scale gene expression studies [top data set from (15) and bottom data set from (16)]. Visualization tools incorporated in Oncomine (10) were used to generate graphical displays. Sample


correlate with increased copy number, no cancer associated genes have been identified from this region (Leinonen 2007). Identification of the target gene of the 9p13.3 amplification might provide a new prognostic marker for prostate cancer and help to understand the molecular mechanisms underlying prostate cancer progression.

Clinical Appropriateness Guidelines Molecular Testing of

Molecular testing and gene expression profiling for occult neoplasms (cancers of unknown primary) is experimental, investigational and unproven. Prostate Cancer Screening Prostate cancer early detection assays (e.g. ConfirmMDx) are medically necessary as outlined in the criteria in the NCCN Prostate Cancer Early Detection GUIDELINE®.

CCAT2, a novel long non-coding RNA in breast cancer

Chromosomal copy number aberrations (CNAs) are common in breast cancer (BC) and involve genomic regions in a frequency and combination that suggest distinct routes of tumor development. Patterns of copy number gains and losses define breast tumors with distinct clinico-pathological features and patient prognosis [7, 8].

Identification of driver copy number alterations in diverse

cancer types. Analysis of drivers across multiple cancer types reveals specificity and commonality across 1460 Molecular Oncology 11 (2017) 1459 1474 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. Driver copy number alterations in cancer W. Zhou et al. - Centennial Archive: An introduction to our history

Gene Expression of Stromal to Recurrent Growth after Castration in the CWR22 Prostate Cancer Xenograft Expression and Gene Copy Number Analysis of ERBB2

Review The role and function of PPARγ in bladder cancer

was reported to display proto-oncogene impacts in metastatic prostate cancer, neuroblastoma and bladder cancer Other signal[20, 21]. Reducing the expression of PPARγ inhibited bladder cancer cell viability [22], specifically in cell lines expressing a gain or enhancement of PPARγ [21, 23]. In addition to its

Functional characterization of genetic alterations in cancer

The development of high throughput methods, such as aCGH and gene expression microarrays, allowed discovery of novel cancer associated genetic alterations. Indeed, analyzing gene expression outliers by microarray identified TMPRSS2-ERG translocation in prostate cancer (18). In addition, systematic loss-of-function and gain-of-function screening

2002/5/25 30 AUA 2002 in Orlando From Kazunari SATO After Meeting

#551 ErbB2 oncogene is not amplified or overexpressed in prostate cancer. Teuvo L Tammela et al. Tampere, Finland Gene Copy Number and Protein Expression of ERBB2 Gene in Prostate Cancer Tumor type Gene copy number by CISH Expression by IHC Diploid Aneuploid Primary Lymph node metastases 14 Hormone-refractory tumors 32 Dept Uro/, Akrta univ Med

Recurrent Fusion of TMPRSS2 and ETS Transcription Factor

outliers in prostate cancer. We identified recurrent gene fusions of the 5' untranslated region of TMPRSS2 to ERG or ETV1 in prostate cancer tissues with outlier expression. By using fluorescence in situ hybridization, we dem-onstrated that 23 of 29 prostate cancer samples harbor rearrangements in ERG or E7V1.

KRAS driven expression signature has prognostic power

The statistical analysis used three types of data: genotype data containing somatic mutations and copy number varia-tions (CNVs), RNA-seq gene expression and microarray gene chip data. Next generation sequencing data (exome sequencing and RNA-seq data) for NSCLC patients including AC and squa-mous cell lung carcinoma was downloaded from The Cancer

siRNA Knockdown of Ribosomal Protein Gene RPL19 Abrogates the

amplifications and copy number changes, particularly those of the region that include oncogene ERBB2, formation of isochro-mosome 17q, duplications, deletions, mutations and other genomic rearrangements. Previously [18], we identified enhanced expression of RPL19 mRNA in prostate cell-lines and tissues to

Clinical Appropriateness Guidelines Molecular Testing of

and copy number variants or rearrangements, if performed 81504 Oncology (tissue of origin), microarray gene expression profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores 81519 Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of

The NCI-MATCH Initiative and the Roles of the GI Pathologist

Decoding the cancer genome: ERBB2 (HER2) Breast cancer RNA will be used for research -grade gene expression profiling by Copy Number Variants, n=49.

Cancer Research Transforming Properties of 8p11-12 Amplified

with poor prognosis. Earlier, we used genomic analysis of copy number and gene expression to perform a detailed analysis of the 8p11-12 amplicon to identify candidate oncogenes in breast cancer. We identified 21 candidate genes and provided evidence that three genes, namely, LSM-1, TC-1, and BAG4, have transforming properties when overexpressed.

Genome-Focused Data in Cancer Integrated Data Systems for

cancer center Paradigm shift in biological research Old biology: measure one/two things in two/three conditions ♦ High cost per measurement ♦ Analysis straightforward ♦ Enormously difficult to work out pathways New biology: measure 10,000 things under many conditions ♦ Low cost per measurement ♦ Analysis no longer straightforward, but